Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Toltrazuril is an antiprotozoal medication, specifically a coccidiostat, belonging to the triazine derivative class. It is primarily used in veterinary medicine to treat and prevent coccidiosis in various animals, including poultry, pigs, cattle, sheep, dogs, and cats. The drug works by disrupting the life cycle of coccidia parasites (such as Eimeria, Isospora, and Cyclospora species) within the host's intestinal cells. Its mechanism involves interfering with the protozoa's ability to reproduce, damaging their cellular structures, disrupting nuclear division, and impairing mitochondrial function, which leads to energy depletion and the destruction of the parasites at all life stages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on toltrazuril.